<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02704780</url>
  </required_header>
  <id_info>
    <org_study_id>HawlerMU</org_study_id>
    <nct_id>NCT02704780</nct_id>
  </id_info>
  <brief_title>Two Different Regimens of Misoprostol in Retained Placenta</brief_title>
  <official_title>Umbilical Vein Injection of 800µg Misoprostol Versus 400 µg Misoprostol in the Treatment of Retained Placenta: A Multicenter, Randomized Double Blind Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hawler Medical University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hawler Medical University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study evaluates intra umbilical vein injection of 800 µg versus 400 µg misoprostol for
      the treatment of retained placenta to reduce the need of manual removal of placenta under
      general anaesthesia
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The third stage of labor may be complicated by retained placenta, which may cause severe
      bleeding and infection, with a potentially fatal outcome. Manual removal of placenta is the
      current standard of management of retained placenta which usually requires general or
      regional anaesthesia at a hospital and it is an invasive procedure that may lead to bleeding,
      trauma and infection. Intraumbilical injection of uterotonic agent( misoprostol) is an easy,
      non invasive procedure. A randomized clinical trial are required to determine the difference
      between two doses of misoprostol 400 versus 800 micro gram for management of retained
      placenta
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2016</start_date>
  <completion_date type="Actual">February 14, 2019</completion_date>
  <primary_completion_date type="Actual">February 1, 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Delivery of placenta after injection of of 400 Microgram intraumbilical misoprostol versus 800 microgram of misoprostol</measure>
    <time_frame>up to 30 minutes after intraumbilical injection</time_frame>
    <description>complete delivery of placenta after injection of intraumbilical misoprostol</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The amount of blood loss vaginally in both groups</measure>
    <time_frame>up to 30 minutes after injection of placenta</time_frame>
    <description>To estimate the amount of vaginal blood loss from time of injection of the the interventional drug and till the delivery of the placenta</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The time of delivery of placenta in both groups</measure>
    <time_frame>up to 30 minutes after delivery of the placenta</time_frame>
    <description>the time interval estimation from the injection to complete delivery of the placenta</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>side effects of misoprostol</measure>
    <time_frame>up to 24 hours after delivery of placenta</time_frame>
    <description>Any side effects related to misoprostol after the injection (Fever, severing , diarrhea)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">509</enrollment>
  <condition>Postpartum Haemorrhage</condition>
  <condition>Retained Placenta</condition>
  <arm_group>
    <arm_group_label>400 Microgram Misoprostol</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Misoprostol 400 micro-gram dissolved in 20 mL normal saline will be injected in the umbilical vein in the first group</description>
  </arm_group>
  <arm_group>
    <arm_group_label>800 Microgram Misoprostol</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Misoprostol 800 micro-gram dissolved in 20 mL normal saline will be injected in umbilical cord of the second group</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Misoprostol</intervention_name>
    <description>2 regimes of misoprostol 400 microgram and 800 microgram injections used for 2 groups of women</description>
    <arm_group_label>400 Microgram Misoprostol</arm_group_label>
    <arm_group_label>800 Microgram Misoprostol</arm_group_label>
    <other_name>Cytotic</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  women with a singleton pregnancy, delivered vaginally

          -  28 weeks of gestation and more,

          -  had a prolonged third stage of labor (more than 30 minutes) despite active management,

          -  Haemodynamically stable and accept to participate in the trial

        Exclusion Criteria:

          -  multiple pregnancies,

          -  previous caesarean delivery,

          -  haemodynamically instability, severe anaemia (haemoglobin concentration &lt;8 g/dL),

          -  chorioamnionitis

          -  Refused to participate in the trial
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>15 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Shahla K. Alalaf, professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hawler Medical University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Namir G. Al Tawil, Professor</last_name>
    <role>Study Director</role>
    <affiliation>Hawler Medical University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ariana Kh. Jawad, Assistant professor</last_name>
    <role>Study Chair</role>
    <affiliation>KBMS</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Bahar Q. Muhammad, CABOG</last_name>
    <role>Study Chair</role>
    <affiliation>Maternity Teaching Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jinan N. Hassan, IBMS</last_name>
    <role>Study Chair</role>
    <affiliation>Duhok university</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Salim A. Salim, Master</last_name>
    <role>Study Chair</role>
    <affiliation>Azhar University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Khalida M. Ameen, CABOG</last_name>
    <role>Study Chair</role>
    <affiliation>Karkuk Medical college</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Maryam B. Mahmood, FICOG</last_name>
    <role>Study Chair</role>
    <affiliation>Sulaimani Maternity Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Khansa H. Abdul Rahman, MBChB</last_name>
    <role>Study Chair</role>
    <affiliation>Maternity Teaching Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hawler Medical university</name>
      <address>
        <city>Erbil</city>
        <state>Kurdistan Region</state>
        <zip>44001</zip>
        <country>Iraq</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Iraq</country>
  </location_countries>
  <verification_date>February 2019</verification_date>
  <study_first_submitted>February 19, 2016</study_first_submitted>
  <study_first_submitted_qc>March 9, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 10, 2016</study_first_posted>
  <last_update_submitted>February 21, 2019</last_update_submitted>
  <last_update_submitted_qc>February 21, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">February 22, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Hawler Medical University</investigator_affiliation>
    <investigator_full_name>Shahla Alalaf</investigator_full_name>
    <investigator_title>Professor Shahla K.Alalaf</investigator_title>
  </responsible_party>
  <keyword>Retained placenta</keyword>
  <keyword>Misoprostol</keyword>
  <keyword>double blind</keyword>
  <keyword>Randomization</keyword>
  <keyword>Haemorrhage</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Postpartum Hemorrhage</mesh_term>
    <mesh_term>Placenta, Retained</mesh_term>
    <mesh_term>Hemorrhage</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Misoprostol</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

